查看购物车
  • Traditional Chinese
  • English
2021-2031年欧洲治疗性疫苗市场报告：范围、细分、动态和竞争分析
市场调查报告书
商品编码
1871434

2021-2031年欧洲治疗性疫苗市场报告：范围、细分、动态和竞争分析

Europe Therapeutic Vaccines Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 133 Pages | 订单完成后即时交付

价格

欧洲治疗性疫苗市场预计将大幅成长，到 2031 年将达到约 147.6 亿美元，高于 2024 年的 63.9 亿美元，2024 年至 2031 年的年复合成长率(CAGR) 为 12.7%。

执行摘要和市场分析

欧洲治疗性疫苗市场分为多个区域，包括德国、英国、法国、义大利、西班牙和欧洲其他地区。该市场的成长主要得益于先进的医疗保健体系和研发投入的增加。欧洲拥有许多领先的製药和生物技术公司，致力于开发各种疾病（尤其是癌症）的创新疫苗疗法。慢性病发病率的上升以及人们对个人化医疗日益增长的兴趣，进一步推动了该地区对治疗性疫苗的需求。预计在免疫疗法的进步和新型疫苗技术的涌现的推动下，该市场将继续保持上升势头，这些进步和技术为市场成长带来了巨大的机会。

市场区隔分析

治疗性疫苗市场可依产品类型、技术和最终用户进行细分：

  • 按产品划分：市场包括癌症疫苗、传染病疫苗等，其中癌症疫苗在 2024 年将占据最大的市场份额。
  • 按技术划分：市场分为同种异体疫苗和自体疫苗，到 2024 年，同种异体疫苗将占据市场份额的领先地位。
  • 按最终用户划分：最终用户主要是医院、诊所和其他机构，其中医院在 2024 年将占最大份额。

市场展望

治疗性疫苗旨在刺激免疫系统，以治疗癌症、自体免疫疾病和慢性感染等疾病。疫苗研发投入的不断增加对于治疗性疫苗市场的成长至关重要，它能够促进创新并加速慢性病新疗法的研发。过去十年，全球疫苗研发资金大幅成长，各国政府、私人机构和製药公司都意识到治疗性疫苗在满足未被满足的医疗需求方面发挥关键作用。例如，葛兰素史克（GSK）在2021年投入64.6亿美元用于研发，重点在于包含43种药物和21种疫苗的研发管线，其中相当一部分针对传染病。

此外，肿瘤疫苗领域呈现显着的研发趋势，许多公司正利用mRNA技术开发针对多种癌症的治疗性疫苗。例如，eTheRNA Immunotherapies公司获得了欧盟委员会690万欧元的资助，用于开发一种创新的mRNA癌症疫苗，以治疗復发性或转移性HPV16阳性癌症。同样，贝尔法斯特女王大学的研究人员也获得了资助，探索三阴性乳癌的新疗法，重点是开发一种mRNA疫苗，以增强免疫系统靶向携带p53突变的癌细胞的能力。这类资助计画正在推动治疗性疫苗的创新，为包括癌症和慢性感染在内的多种疾病带来更有效的治疗方法。

国家概况

欧洲治疗性疫苗市场涵盖德国、义大利、法国、英国、西班牙等主要国家，其中德国在2024年占据最大的市场份额。德国拥有全球最先进的医疗保健体系之一，其强大的製药和生物技术产业为治疗性疫苗的研发和商业化提供了有力支持。德国拥有庞大的患者群体，对高品质医疗保健服务的需求旺盛。慢性病和传染病（例如B型肝炎）的日益普及进一步推动了德国市场的发展。例如，2022年德国报告了16,674例乙型肝炎病例。

德国强大的科学研究生态系统，以学术机构、医院和生技公司之间的合作为特征，正在加速新型治疗性疫苗的研发。德国癌症研究中心（DKFZ）处于癌症免疫疗法研究的前沿，为德国的创新格局做出了重大贡献。 2024年8月，DKFZ的研究人员推出了一种旨在提高HPV疫苗接种率的新型疫苗，该疫苗已被证实能够有效预防多种致癌型HPV病毒感染。

公司简介

治疗性疫苗市场的主要参与者包括CureVac SE、THERAVECTYS SA、Transgene SA、INOVIO Pharmaceuticals Inc、ISA Pharmaceuticals BV、Amgen Inc、Merck & Co Inc、印度血清研究所、BioNTech SE和Dendreon。这些公司正采取多种策略，包括扩张、产品创新以及併购，以增强其市场份额并为消费者提供创新产品。

目录

第一章：引言

第二章：执行概要

  • 关键见解

第三章：研究方法

  • 二手研究
  • 初步研究
    • 假设的提出：
    • 宏观经济因素分析：
    • 发展基础数字：
    • 数据三角测量：
    • 国家层面资料：

第四章：欧洲治疗性疫苗市场－主要市场动态

  • 市场驱动因素
    • 慢性病盛行率上升
    • 增加疫苗研发的投资与资金投入
  • 市场限制
    • 监管挑战
  • 市场机会
    • 拓展产品线
  • 未来趋势
    • 疫苗技术的进步
  • 驾驶员和安全带的影响：

第五章：治疗性疫苗市场－欧洲市场分析

  • 2021-2031年欧洲治疗性疫苗市场收入
  • 欧洲治疗性疫苗市场预测分析

第六章：欧洲治疗性疫苗市场分析－依产品分类

  • 癌症疫苗
  • 传染病疫苗
  • 其他的

第七章：欧洲治疗性疫苗市场分析－依技术划分

  • 同种异体疫苗
  • 自体疫苗

第八章：欧洲治疗性疫苗市场分析－以最终用户划分

  • 医院
  • 诊所
  • 其他的

第九章：欧洲治疗性疫苗市场—国别分析

  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区

第十章：治疗性疫苗市场－产业概况

  • 概述
  • 治疗性疫苗市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第十一章：公司简介

  • Dendreon
  • BioNTech SE
  • Serum Institute of India Pvt. Ltd
  • Merck & Co Inc
  • Amgen Inc
  • ISA Pharmaceuticals BV
  • INOVIO Pharmaceuticals Inc
  • Transgene SA
  • THERAVECTYS SA
  • CureVac SE

第十二章：附录

Product Code: BMIRE00032091

The Europe therapeutic vaccines market is projected to grow significantly, reaching approximately US$ 14.76 billion by 2031, up from US$ 6.39 billion in 2024, with a compound annual growth rate (CAGR) of 12.7% during the period from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccines market in Europe is divided into several regions, including Germany, the UK, France, Italy, Spain, and the Rest of Europe. The growth of this market is driven by advanced healthcare systems and increased investments in research and development. Europe hosts numerous leading pharmaceutical and biotechnology companies that are dedicated to developing innovative vaccine therapies for various diseases, particularly cancer. The rising incidence of chronic diseases and the growing interest in personalized medicine are further propelling the demand for therapeutic vaccines in the region. The market is expected to continue its upward trajectory, bolstered by advancements in immunotherapy and the emergence of new vaccine technologies that present significant opportunities for growth.

Market Segmentation Analysis

The therapeutic vaccines market can be segmented based on product type, technology, and end user:

  • By Product: The market includes cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
  • By Technology: The market is categorized into allogenic and autologous vaccines, with allogenic vaccines leading in market share in 2024.
  • By End User: The end users are primarily hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

Therapeutic vaccines are designed to stimulate the immune system to treat conditions such as cancer, autoimmune diseases, and chronic infections. The increasing investments in vaccine development are crucial for the growth of the therapeutic vaccines market, fostering innovation and accelerating the creation of new treatments for chronic diseases. Over the last decade, global funding for vaccine R&D has surged, with governments, private entities, and pharmaceutical companies acknowledging the critical role of therapeutic vaccines in meeting unmet medical needs. For example, GlaxoSmithKline (GSK) allocated US$ 6.46 billion towards R&D in 2021, focusing on a pipeline that includes 43 medicines and 21 vaccines, with a significant portion targeting infectious diseases.

Moreover, there is a notable trend towards oncology-focused vaccines, with companies leveraging mRNA technology to develop therapeutic vaccines for various cancers. For instance, eTheRNA Immunotherapies received a €6.9 million grant from the European Commission to develop an innovative mRNA cancer vaccine for treating recurrent or metastatic HPV16+ cancers. Similarly, researchers at Queen's University Belfast secured funding to explore new treatments for triple-negative breast cancer, focusing on developing an mRNA vaccine that enhances the immune system's ability to target cancer cells with p53 mutations. Such funding initiatives are driving innovations in therapeutic vaccines, leading to more effective treatments for a range of diseases, including cancers and chronic infections.

Country Insights

The therapeutic vaccines market in Europe includes key countries such as Germany, Italy, France, the UK, Spain, and others, with Germany holding the largest market share in 2024. Germany boasts one of the most advanced healthcare systems globally, supported by a robust pharmaceutical and biotechnology sector that facilitates the development and commercialization of therapeutic vaccines. The country has a large patient population and a high demand for quality healthcare services. The increasing prevalence of chronic and infectious diseases, such as hepatitis B, further drives the market in Germany. For instance, in 2022, Germany reported 16,674 cases of hepatitis B.

Germany's strong research ecosystem, characterized by collaboration among academic institutions, hospitals, and biotech firms, is accelerating the development of new therapeutic vaccines. The German Cancer Research Center (DKFZ) is at the forefront of cancer immunotherapy research, contributing significantly to the country's innovation landscape. In August 2024, DKFZ researchers introduced a novel vaccine aimed at increasing HPV vaccination rates, demonstrating efficacy in protecting against various cancer-causing HPV types.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and deliver innovative products to consumers.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:

4. Europe Therapeutic Vaccines Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Chronic Conditions
    • 4.1.2 Increasing Investments and Funding for Vaccine Development
  • 4.2 Market Restraints
    • 4.2.1 Regulatory Challenges
  • 4.3 Market Opportunities
    • 4.3.1 Extending Product Pipeline
  • 4.4 Future Trends
    • 4.4.1 Advancements in Vaccine Technology
  • 4.5 Impact of Drivers and Restraints:

5. Therapeutic Vaccines Market - Europe Market Analysis

  • 5.1 Europe Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • 5.2 Europe Therapeutic Vaccines Market Forecast Analysis

6. Europe Therapeutic Vaccines Market Analysis - by Product

  • 6.1 Cancer Vaccine
    • 6.1.1 Overview
    • 6.1.2 Cancer Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.2 infectious Disease Vaccine
    • 6.2.1 Overview
    • 6.2.2 infectious Disease Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 6.3 Others
    • 6.3.1 Overview
    • 6.3.2 Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

7. Europe Therapeutic Vaccines Market Analysis - by Technology

  • 7.1 Allogenic Vaccine
    • 7.1.1 Overview
    • 7.1.2 Allogenic Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 7.2 Autologous Vaccine
    • 7.2.1 Overview
    • 7.2.2 Autologous Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. Europe Therapeutic Vaccines Market Analysis - by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Hospitals: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.2 Clinics
    • 8.2.1 Overview
    • 8.2.2 Clinics: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.3 Others
    • 8.3.1 Overview
    • 8.3.2 Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. Europe Therapeutic Vaccines Market - Country Analysis

  • 9.1 Europe
    • 9.1.1 Europe Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.1 Europe Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.2.1 Germany: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.2.2 Germany: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.2.3 Germany: Europe Therapeutic Vaccines Market Share - by End User
      • 9.1.1.3 United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.3.1 United Kingdom: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.3.2 United Kingdom: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.3.3 United Kingdom: Europe Therapeutic Vaccines Market Share - by End User
      • 9.1.1.4 France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.4.1 France: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.4.2 France: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.4.3 France: Europe Therapeutic Vaccines Market Share - by End User
      • 9.1.1.5 Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.5.1 Italy: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.5.2 Italy: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.5.3 Italy: Europe Therapeutic Vaccines Market Share - by End User
      • 9.1.1.6 Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.6.1 Spain: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.6.2 Spain: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.6.3 Spain: Europe Therapeutic Vaccines Market Share - by End User
      • 9.1.1.7 Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 9.1.1.7.1 Rest of Europe: Europe Therapeutic Vaccines Market Share - by Product
        • 9.1.1.7.2 Rest of Europe: Europe Therapeutic Vaccines Market Share - by Technology
        • 9.1.1.7.3 Rest of Europe: Europe Therapeutic Vaccines Market Share - by End User

10. Therapeutic Vaccines Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Therapeutic Vaccines Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Dendreon
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 BioNTech SE
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Serum Institute of India Pvt. Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Merck & Co Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Amgen Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 ISA Pharmaceuticals BV
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 INOVIO Pharmaceuticals Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Transgene SA
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 THERAVECTYS SA
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 CureVac SE
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. Europe Therapeutic Vaccines Market Segmentation
  • Table 2. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Table 3. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
  • Table 4. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
  • Table 5. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
  • Table 6. Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
  • Table 7. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 8. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 9. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 10. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 11. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 12. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 13. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 14. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 15. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 16. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 17. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 18. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 19. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 20. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 21. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 22. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
  • Table 23. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
  • Table 24. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 25. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
  • Table 26. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
  • Table 27. Glossary of Terms, Therapeutic Vaccines Market

List Of Figures

  • Figure 1. Europe Therapeutic Vaccines Market Segmentation - Country
  • Figure 2. Europe Therapeutic Vaccines Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. Europe Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
  • Figure 6. Cancer Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 7. infectious Disease Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 8. Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 9. Europe Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
  • Figure 10. Allogenic Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 11. Autologous Vaccine: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 12. Europe Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
  • Figure 13. Hospitals: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 14. Clinics: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 15. Others: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 16. Europe Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 17. Germany: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 18. United Kingdom: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 19. France: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 20. Italy: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 21. Spain: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 22. Rest of Europe: Europe Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 23. Growth Strategies in the Therapeutic Vaccines Market